U.S. Stem Cell, Inc. Announces Revenue Results for the Quarter and Financial Results for the Nine Months Ended September 30, 2018
November 08, 2018 at 03:00 am IST
Share
U.S. Stem Cell, Inc. announced revenue results for the quarter and financial results for the nine months ended September 30, 2018. For the quarter, revenue continues to rise from $4.04 million in third quarter 2017 to $5.03 million in third quarter 2018.
For the nine months, revenue continues to rise -- almost $1 million or 25% for the period compared to the same period last year. Net Loss from operations decreased $838,000 or 79.3%, from $1,000,000 to $218,000 during the same nine months ended this year versus last.
U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. MyoCell SDF-1 is similar to MyoCell except that the myoblast cells to be injected for use in MyoCell SDF-1 will be modified prior to injection by an adenovirus vector or non-viral vector. Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.
U.S. STEM CELL, INC. 
